PHA 6279 Pharmaceutical Outcomes & Policy Seminar


Consider this: although 8 in 10 adults say the cost of prescription drugs is unreasonable, only 3 in 10 say they are difficult to afford (KFF 2021). This paradox results from complex system of drug pricing and reimbursement in the US, which often shields people from the true cost of the medications they take. This is one of several incentives that make bringing the price of prescription drugs down so difficult. The 29th Pharmaceutical Outcomes and Policy Seminar will examine the business, economic, and ethical aspects of prescription drug pricing in the context of the complex reimbursement system. Experts will present new policies included in the Inflation Reduction Act and proposed policy solutions, including value-based drug prices and patent reforms. Student and faculty will deliberate the intended and unintended consequences of these policies on patient costs, access, disparity, and innovation – and whether any of these efforts will actually result in lower drug prices.

Tuition: $750
Credits: 1

*Please note that this syllabus is subject to change. Use the updated syllabus in Canvas as the official course syllabus.